Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
TOKYO, June 17, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that it has decided to terminate the development of the DNA vaccine ASP0892, which is currently in Phase 1 study for peanut allergy.
As a result of this termination, Astellas will book an impairment loss of ¥21.5 billion as other expenses in the first quarter of fiscal year 2021.
The impact from this termination is not reflected in Astellas' consolidated financial forecasts for the fiscal year ending March 31, 2022 announced in April 2021.
Click below for a copy of the full press release
Follow us
